Guillain–Barré syndrome

Guillain–Barré syndrome
Name	Guillain–Barré syndrome
Field	Neurology
Symptoms	Rapidly progressive weakness, paresthesia, hyporeflexia
Complications	Respiratory failure, autonomic dysfunction
Onset	Acute, often days to weeks after infection or immunization
Types	Acute inflammatory demyelinating polyneuropathy, Miller Fisher syndrome
Treatment	Intravenous immunoglobulin, plasmapheresis, supportive care

Guillain–Barré syndrome is an acute autoimmune polyradiculoneuropathy characterized by rapidly progressive limb weakness, sensory changes, and reduced reflexes. It often follows an antecedent event such as infection, surgery, or immunization and can progress to respiratory failure requiring ventilation. Presentation, course, and outcomes vary worldwide and across healthcare systems.

Signs and symptoms

Patients classically develop ascending symmetric weakness beginning in the lower extremities and advancing proximally, with paresthesia and numbness. Prominent autonomic disturbances may include tachycardia, labile blood pressure, and urinary retention, sometimes necessitating management in an intensive care unit like those in Johns Hopkins Hospital, Mayo Clinic, or Massachusetts General Hospital. Cranial nerve involvement can produce facial weakness and bulbar dysfunction, relevant to clinicians trained at University of Oxford, Harvard Medical School, or University of Toronto. Pain, fatigue, and sensory ataxia contribute to disability encountered in rehabilitation programs such as MossRehab and Spaulding Rehabilitation Hospital.

Causes and pathophysiology

The syndrome is typically triggered by antecedent infections including Campylobacter jejuni enteritis, Cytomegalovirus infection, and Epstein–Barr virus, or by events such as immunization campaigns like the 1976 United States swine flu vaccination program. Immune-mediated damage targets peripheral nerve myelin or axons through molecular mimicry, complement activation, and macrophage infiltration—mechanisms studied at institutions including Karolinska Institute, Institut Pasteur, and National Institutes of Health. Variants such as acute motor axonal neuropathy and Miller Fisher syndrome have distinct antibody associations, including anti-GM1 and anti-GQ1b, with serologic correlations reported by researchers at Imperial College London, University College London, and Johns Hopkins University.

Diagnosis

Diagnosis relies on clinical features supported by investigations: cerebrospinal fluid analysis showing albuminocytologic dissociation and nerve conduction studies demonstrating demyelination or axonal loss. Electrodiagnostic testing protocols from centers like Cleveland Clinic, Mount Sinai Hospital (New York City), and Toronto General Hospital assist in subtyping. Differential diagnoses include acute myelopathies seen at Karolinska University Hospital, toxic neuropathies reported in exposure incidents, and hereditary neuropathies characterized at University of Cambridge and Stanford University Medical Center.

Treatment and management

First-line immunotherapies are intravenous immunoglobulin (IVIG) and plasma exchange, with evidence synthesized by guideline committees at organizations such as the World Health Organization, European Academy of Neurology, and American Academy of Neurology. Supportive care includes respiratory support in line with protocols from Royal Brompton Hospital, cardiovascular monitoring used at Royal Infirmary of Edinburgh, thromboprophylaxis per practice at Guy's Hospital, and early rehabilitation coordinated with facilities like Craig Hospital and Shepherd Center. Long-term management may involve neurologists affiliated with Columbia University Irving Medical Center or UCSF Medical Center for follow-up and vocational reintegration.

Prognosis and complications

Most patients begin recovery within weeks to months, but a subset experiences prolonged disability, chronic pain, or relapse. Respiratory failure, sepsis, and autonomic instability are major acute complications described in case series from Johns Hopkins Hospital and Mayo Clinic, while long-term sequelae such as fatigue and neuropathic pain have been studied by teams at Oxford University Hospitals and University of Sydney. Predictors of poor outcome include older age, rapid progression, and axonal forms documented in cohorts at University of California, Los Angeles and National University Hospital, Singapore.

Epidemiology

Incidence is roughly 1–2 per 100,000 annually, with variation by geography, season, and antecedent exposures reported in surveillance studies by the Centers for Disease Control and Prevention, Public Health England, and European Centre for Disease Prevention and Control. Large epidemiologic investigations using health systems data from Kaiser Permanente and national registries in Japan and Brazil inform trends related to infectious outbreaks, such as those associated with Zika virus epidemics studied by teams at Universidade de São Paulo and University of Puerto Rico.

Category:Peripheral nervous system disorders